ClinicalTrials.gg
RecruitingNCT05992883Updated Feb 23, 2026

NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis

A Phase 3 interventional study of Ketorolac and Triamcinolone in Thumb Osteoarthritis, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Mayo Clinic · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Osteoarthritis by Mayo Clinic — 2 open to participants now, 4 under way, 1 of them phase 3. Osteoarthritis · Mayo Clinic.

Planned enrollment
2nd of 19
240 · median 40
Started
2023
with 1 other
Phase 3
2 of 21
1 open now
Registered
18th of 21
by date

Among the 21 studies in Osteoarthritis by Mayo Clinic, this one is the 2nd largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 18th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 21 studies in Osteoarthritis by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Osteoarthritis by Mayo Clinic, or all of them as a file.
02

Study summary

The Researchers are trying to compare two different types of intraarticular injections (injection in the joint) for treating the symptoms of moderate to advanced basilar thumb arthritis. One injection is ketorolac (an NSAID) and the other is triamcinolone (a corticosteroid).

Read the detailed description

Cartilage degeneration resulting in osteoarthritis is the most common and costly musculoskeletal disorder in the United States, with basilar thumb arthritis being one of the most common manifestations of this disease. Despite its prevalence and previous research on treatments for the disease, there is a dearth of efficacious and low-cost interventions for trapeziometacarpal arthritis. Of these nonoperative interventions, intraarticular corticosteroid injections are the most popular and have the most evidence indicating their benefit. However, long-term use of corticosteroids has a well-established degenerative effect that is counterproductive to preserving cartilage and bone of the CMC joint. Novel, disease-modifying osteoarthritis treatments such as platelet rich plasma and human recombinant bone morphogenic protein 7, among others, are alternative options for patients. Many of these are currently in advanced development, but to date none have achieved FDA approval, and all are significantly more expensive and have limited availability compared to intraarticular corticosteroids.

Although used infrequently, non-steroidal anti-inflammatory drugs (NSAIDs) are another modality of nonoperative intervention for basilar thumb arthritis. Intraarticular injections of NSAIDs have demonstrated success in alleviating the symptoms of primary arthritis in the hip and knee without concern of systemic side effects compared to oral NSAID use. Additionally, injectable NSAIDs are significantly more cost-effective compared to other injectables and do not have the chondrotoxic profile of corticosteroids. However, there are few studies directly comparing intraarticular NSAID use to other injectable therapies.

Given the potential clinical and economic benefits of injectable NSAID therapy, we propose a clinical trial investigation examining the efficacy of intraarticular ketorolac versus intraarticular triamcinolone in treating symptoms of moderate to advanced primary osteoarthritis of the basilar thumb. The prospect of successfully alleviating symptoms of joint degeneration without propagating the progression of disease would be invaluable to the thousands of patients in the Mayo Clinic system and elsewhere afflicted with basilar thumb arthritis without the means or ability to pursue stem cell therapeutics or more definitive, operative intervention.

03

Conditions studied

  • Thumb Osteoarthritis

Browse trials for

Keywords

  • Injection
  • Steroid
  • NSAID
  • Thumb Arthritis
  • CMC Arthritis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults >40 years of age
  • Pain at the thumb base brought on by direct pressure (grind test) and with movement
  • Pain resistant to previous conservative management (including over the counter medications (ibuprofen/acetaminophen), icing, splinting/braces, or topical analgesics)
  • Radiological observation indicative of arthritis based on the Eaton-Littler classification system (stages 1 through 4)
  • Patient understands the protocol and signed the
  • Patient is covered by health insurance

Exclusion criteria

Exclusion Criteria:

    • Known allergy to either of the treatment products
  • Patient's analgesic treatment regimen or other modalities of managing symptoms/pain associated with their hand pathology was modified within four weeks before trial inclusion
  • Symptomatic Scaphoid-trapezial arthritis present
  • Localized or systemic infection
  • Previous thumb surgery on study thumb
  • Previous thumb injury on study thumb
  • Patient with inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis)
  • Severe and/or uncontrolled hypertension
  • De Quervain tendinopathy present
  • History of injection to the trapeziometacarpal joint on study thumb within the previous 6 weeks
  • Uncontrolled diabetes
  • Pregnant or lactating females. Female participants of must have a negative pregnancy test before the injection. Women without childbearing potential (ie., surgically sterile with hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy OR ≥ 12 months of amenorrhea and at least 50 years of age) are eligible to participate without completing a pregnancy test.
  • Immunodeficient patients
  • Patients that are currently using nicotine products, or who have quit in the last 12 months
  • Patients under guardianship, curatorship, or are otherwise not self-sufficient
  • Patients participating in another clinical research trial which interferes with this study protocol or outcomes
  • Patients unable to follow the protocol in the investigators' judgement.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Non-steroidal anti-inflammatory drug (NSAID)

    Patients will proceed to their injection appointment within 4 weeks of their initial evaluation. At the injection appointment, patients will receive an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).

    Drug: Ketorolac

  • Active comparator
    Corticosteroid

    Patients will proceed to their injection appointment within 4 weeks of their initial evaluation. At the injection appointment, patients will receive an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).

    Drug: Triamcinolone

Interventions

  • Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).

    Also known as: Toradol

  • Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale (VAS) of Pain

    Patient-reported VAS score with both motion and rest of the CMC joint. The VAS is a 11-item questionnaire assessing pain. Using a scale of 0 = no pain to 10 = worst pain. Total scores range from 0 - 110, lower scores indicating lower pain and higher scores indicating greater pain.

    Time frame: At initial evaluation and then 1 month, 3 months, 6 months, and 1 year post-injection.

Secondary outcomes

  1. Michigan Hand Outcomes Questionnaire (MHQ)

    The Michigan Hand Outcomes Questionnaire (MHQ) is patient-reported. An overall MHQ score can be obtained by summing the scores for all six scales after reversing the pain scale (pain=100-pain score) and then dividing by six. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.

    Time frame: At initial evaluation and then 1 month, 3 months, 6 months, and 1 year post-injection.

  2. Grip Strength

    Grip strength measured with a dynamometer, reported in kilograms. Measurements will be performed three times, with the mean value of the three repetitions used as the reported value.

    Time frame: At initial evaluation and then 1 month, 3 months, 6 months, and 1 year post-injection.

  3. Apposition Strength

    Apposition strength measured with a dynamometer, reported in kilograms. Measurements will be performed three times, with the mean value of the three repetitions used as the reported value.

    Time frame: At initial evaluation and then 1 month, 3 months, 6 months, and 1 year post-injection.

  4. Opposition Strength

    Opposition strength measured with a dynamometer, reported in kilograms. Measurements will be performed three times, with the mean value of the three repetitions used as the reported value.

    Time frame: At initial evaluation and then 1 month, 3 months, 6 months, and 1 year post-injection.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

Of 84 phase 3 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 27. This study's planned 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 15, 2023
StartActual
Jul 28, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05992883
Lead sponsor
Mayo Clinic
Responsible party
Marco Rizzo (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 15, 2023
Start date
Jul 28, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 23, 2026

Study contacts

Lindsey Hobbs
Contact
hobbs.lindsey@mayo.edu
5072939765
Marco Rizzo, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketorolac

Start the discussion